Baseline data
| Normal coronaries (148) | Coronary disease (n=930) | Difference (p value) | Coronary disease cohort | |||
| Bio-T <2.6 nmol/l (n=194) | Bio-T >2.6 nmol/l (n=736) | Difference (p value) | ||||
| Age (trial entry), years | 55.5±11.3 | 60.7±9.4 | 0.0001* | 63±9.1 | 60.1±9.5 | 0.0001* |
| BMI (kg/m2) | 27.7±4.8 | 28.0±4.1 | 0.36* | 28.9±4.2 | 27.8±4.1 | 0.001* |
| Alcohol units/week | 11.2±13.6 | 8.8±11.7 | 0.02* | 9.8±16.0 | 8.57±10.2 | 0.2* |
| Glucose, mmol/l | 5.4±1.7 | 6.2±3.1 | 0.005* | 6.6±3.5 | 6.1±3.0 | 0.09 |
| Three vessel | 362 (39%) | 81 (42%) | 281 (38%) | 0.32 | ||
| Two vessel | 237 (26%) | 48 (25%) | 189 (26%) | 0.9 | ||
| One vessel | 238 (26%) | 44 (23%) | 194 (26%) | 0.35 | ||
| Plaque | 83 (9%) | 17 (9%) | 66 (9%) | 1 | ||
| Mild LVSI | 14 (9%) | 216 (23%) | 0.0001† | 40 (21%) | 176 (24%) | 0.4 |
| Moderate LVSI | 3 (2%) | 72 (8%) | 0.006† | 13 (7%) | 59 (8%) | 0.7 |
| Severe LVSI | 8 (5%) | 21 (2%) | 0.05† | 7 (4%) | 14 (2%) | 0.17 |
| Never smoked | 49 (33%) | 229 (25%) | 0.03† | 35 (18%) | 194 (26%) | 0.02† |
| Active smoker | 25 (17%) | 128 (14%) | 0.3 | 16 (8%) | 112 (15%) | 0.01† |
| Diabetes | 8 (5%) | 126 (14%) | 0.004† | 32 (16%) | 94 (13%) | 0.2 |
| Hypertension | 43 (29%) | 439 (47%) | 0.0001† | 104 (54%) | 335 (46%) | 0.05† |
| Lipid-lowering therapy | 50 (34%) | 667 (72%) | 0.0001† | 147 (76%) | 520 (71%) | 0.2 |
| Aspirin | 84 (57%) | 776 (83%) | 0.0001† | 154 (79%) | 622 (85%) | 0.1 |
| ACE/ARB | 42 (28%) | 298 (32%) | 0.4 | 70 (36%) | 228 (31%) | 0.2 |
| β-blocker | 68 (46%) | 633 (68%) | 0.0001† | 125 (64%) | 508 (69%) | 0.2 |
| Nitrate | 24 (16%) | 379 (41%) | 0.0001† | 80 (41%) | 299 (41%) | 0.9 |
| TT, nmo/l | 13.9±7.1 | 13.9±7.4 | 0.9 | |||
| Bio-T, nmol/l | 4.4±2.5 | 4.3±2.5 | 0.6 | |||
| Dead | 16 (11%) | 129 (14%) | 0.4 | 41 (21%) | 88 (12%) | 0.002† |
| Survival time, days | 2562±573 | 2505±652 | 2347±759 | 2547±615 | 0.0001* | |